Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Трудности дифференциальной диагностики нарушений углеводного обмена у больных коронавирусной инфекцией в реальной клинической практике
Трудности дифференциальной диагностики нарушений углеводного обмена у больных коронавирусной инфекцией в реальной клинической практике
Маркова Т.Н., Стас М.С., Чибисова В.В., Анчутина А.А. Трудности дифференциальной диагностики нарушений углеводного обмена у больных коронавирусной инфекцией в реальной клинической практике. Consilium Medicum. 2023;25(4):241–246. DOI: 10.26442/20751753.2023.4.202216
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Проблема влияния коронавирусной инфекции на углеводный обмен остается открытой. В ходе заболевания выявляются различные нарушения углеводного обмена, в том числе впервые выявленный сахарный диабет и транзиторная гипергликемия. В данной статье представлены два клинических случая с разным течением и длительностью стрессовой транзиторной гипергликемии на фоне коронавирусной инфекции.
Ключевые слова: коронавирусная инфекция, COVID-19, сахарный диабет, транзиторная гипергликемия
Keywords: coronavirus infection, COVID-19, diabetes mellitus, transient hyperglycemia
Ключевые слова: коронавирусная инфекция, COVID-19, сахарный диабет, транзиторная гипергликемия
________________________________________________
Keywords: coronavirus infection, COVID-19, diabetes mellitus, transient hyperglycemia
Полный текст
Список литературы
1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet.
2020;395(10229):1054-62. DOI:10.1016/S0140-6736(20)30566-3
2. Lee MH, Wong C, Ng CH, et al. Effects of hyperglycaemia on complications of COVID-19: A meta-analysis of observational studies. Diabetes Obes Metab. 2021;23(1):287-9. DOI:10.1111/dom.14184
3. Калмыкова З.А., Кононенко И.В., Скляник И.А., и др. Гипергликемия и возможные механизмы повреждения β-клеток у пациентов с COVID-19. Сахарный диабет. 2020;23(3):229-34 [Kalmykova ZA, Kononenko IV, Sklyanik IA, et al. Hyperglycemia and possible mechanisms of β-cell damage in patients with COVID-19. Diabetes mellitus. 2020;23(3):229-34 (in Russian)]. DOI:10.14341/DM12485
4. Govender N, Khaliq OP, Moodley J, Naicker T. Insulin resistance in COVID-19 and diabetes. Prim Care Diabetes. 2021;15(4):629-34. DOI:10.1016/j.pcd.2021.04.004
5. Senapati S, Banerjee P, Bhagavatula S, et al. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19. J Genet. 2021;100(1):12. DOI:10.1007/s12041-021-01262-w
6. Fadini GP, Morieri ML, Boscari F, et al. Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration. Diabetes Res Clin Pract. 2020;168:108374. DOI:10.1016/j.diabres.2020.108374
7. Sathish T, Kapoor N, Cao Y, et al. Proportion of newly diagnosed diabetes in COVID-19 patients: A systematic review and meta-analysis. Diabetes Obes Metab. 2021;23(3):870-4. DOI:10.1111/dom.14269
8. Lee MS, Lee R, Ko CW, Moon JE. Increase in blood glucose level and incidence of diabetic ketoacidosis in children with type 1 diabetes mellitus in the Daegu-Gyeongbuk area during the coronavirus disease 2019 (COVID-19) pandemic: a retrospective cross-sectional study. J Yeungnam Med Sci. 2022;39(1):46-52. DOI:10.12701/yujm.2021.01221
9. Шестакова М.В., Кононенко И.В., Калмыкова З.А., и др. Повышенный уровень гликированного гемоглобина (HbA1c) у больных с COVID-19 является маркером тяжести течения инфекции, но не индикатором предшествующего сахарного диабета. Сахарный диабет. 2020;23(6):504-13 [Shestakova MV, Kononenko IV, Kalmykova ZA, et al. High level of glycated hemoglobin (HbA1c) in patients with COVID-19 is a marker of the severity of the infection but not an indicator of previous diabetes mellitus. Diabetes mellitus. 2020;23(6):504-13 (in Russian)]. DOI:10.14341/DM12702
10. Хайдарова Ф.А., Алимова Н.У., Алиева А.В., и др. Влияние COVID-19-инфекции на развитие сахарного диабета 1 типа у детей и подростков. Сахарный диабет. 2022;25(1):21-6 [Khaydarova FA, Alimova NU, Alieva AV, et al. Impact of COVID-19 infection on the development of type 1 diabetes mellitus in children and adolescents. Diabetes mellitus. 2022;25(1):21-6 (in Russian)]. DOI:10.14341/DM12785
11. Маркова Т.Н., Лысенко М.А., Иванова А.А., и др. Распространенность нарушений углеводного обмена у пациентов с новой коронавирусной инфекцией. Сахарный диабет. 2021;24(3):222-30 [Markova TN, Lysenko MA, Ivanova AA, et al. Prevalence of carbohydrate metabolism disorders in patients with new coronavirus infection. Diabetes mellitus. 2021;24(3):222-30 (in Russian)]. DOI:10.14341/DM12712
12. Da Porto A, Tascini C, Colussi G, et al. Relationship between cytokine release and stress hyperglycemia in patients hospitalized with COVID-19 infection. Front Med (Lausanne). 2022;9:988686. DOI:10.3389/fmed.2022.988686
13. Ilias I, Jahaj E, Kokkoris S, et al. Clinical Study of Hyperglycemia and SARS-CoV-2 Infection in Intensive Care Unit Patients. In Vivo. 2020;34(5):3029-32. DOI:10.21873/invivo.12136
14. Zhu L, She ZG, Cheng X, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020;31(6):1068-77.e3. DOI:10.1016/j.cmet.2020.04.021
15. Li H, Tian S, Chen T, et al. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19. Diabetes Obes Metab. 2020;22(10):1897-906. DOI:10.1111/dom.14099
16. Маркова Т.Н., Анчутина А.А., Лысенко М.А. Глюкоза плазмы натощак как фактор риска неблагоприятного исхода у госпитализированных пациентов с COVID-19. Сборник тезисов IX (XXVIII) Национальный диабетологический конгресс с международным участием «Сахарный диабет и ожирение – неинфекционные междисциплинарные пандемии XXI века». 05–08 сентября 2022 года. М., 2022 [Markova TN, Anchutina AA, Lysenko MA. Glyukoza plazmy natoshchak kak faktor riska neblagopriiatnogo iskhoda u gospitalizirovannykh patsiientov s COVID-19. Sbornik tezisov IX (XXVIII) Natsional'nyi diabetologicheskii kongress s mezhdunarodnym uchastiiem “Sakharnyi diabet i ozhireniie – neinfektsionnyie mezhdistsiplinarnyie pandemii XXI veka”. 05–08 sentiabria 2022 goda. Moscow, 2022 (in Russian)].
17. Дедов И.И., Мокрышева Н.Г., Шестакова М.В., и др. Контроль гликемии и выбор антигипергликемической терапии у пациентов с сахарным диабетом 2 типа и COVID-19: консенсусное решение совета экспертов Российской ассоциации эндокринологов. Сахарный диабет. 2022;25(1):27-49 [Dedov II, Mokrysheva NG, Shestakova MV, et al. Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists. Diabetes mellitus. 2022;25(1):27-49 (in Russian)].
18. Barrett CE, Koyama AK, Alvarez P, et al. Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years – United States, March 1, 2020 – June 28, 2021. MMWR Morb Mortal Wkly Rep. 2022;71(2):59-65. DOI:10.15585/mmwr.mm7102e2
19. Стронгин Л.Г., Некрасова Т.А., Беликина Д.В., и др. Дисгликемия при COVID-19 и сахарном диабете 2 типа: особенности гликемического профиля у госпитализированных пациентов и роль стероид-индуцированных нарушений. Проблемы эндокринологии. 2022;68(2):56-65 [Strongin LG, Nekrasova TA, Belikina DV, et al. Dysglycemia in COVID-19 and Type 2 Diabetes Mellitus: Peculiarities of the Glycemic Profile in Hospitalized Patients and the Role of Steroid-Induced Disorders. Problems of Endocrinology. 2022;68(2):56-65 (in Russian)]. DOI:10.14341/probl12840
20. Kuchay MS, Reddy PK, Gagneja S, et al. Short term follow-up of patients presenting with acute onset diabetes and diabetic ketoacidosis during an episode of COVID-19. Diabetes Metab Syndr. 2020;14(6):2039-41. DOI:10.1016/j.dsx.2020.10.015
2020;395(10229):1054-62. DOI:10.1016/S0140-6736(20)30566-3
2. Lee MH, Wong C, Ng CH, et al. Effects of hyperglycaemia on complications of COVID-19: A meta-analysis of observational studies. Diabetes Obes Metab. 2021;23(1):287-9. DOI:10.1111/dom.14184
3. Kalmykova ZA, Kononenko IV, Sklyanik IA, et al. Hyperglycemia and possible mechanisms of β-cell damage in patients with COVID-19. Diabetes mellitus. 2020;23(3):229-34 (in Russian). DOI:10.14341/DM12485
4. Govender N, Khaliq OP, Moodley J, Naicker T. Insulin resistance in COVID-19 and diabetes. Prim Care Diabetes. 2021;15(4):629-34. DOI:10.1016/j.pcd.2021.04.004
5. Senapati S, Banerjee P, Bhagavatula S, et al. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19. J Genet. 2021;100(1):12. DOI:10.1007/s12041-021-01262-w
6. Fadini GP, Morieri ML, Boscari F, et al. Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration. Diabetes Res Clin Pract. 2020;168:108374. DOI:10.1016/j.diabres.2020.108374
7. Sathish T, Kapoor N, Cao Y, et al. Proportion of newly diagnosed diabetes in COVID-19 patients: A systematic review and meta-analysis. Diabetes Obes Metab. 2021;23(3):870-4. DOI:10.1111/dom.14269
8. Lee MS, Lee R, Ko CW, Moon JE. Increase in blood glucose level and incidence of diabetic ketoacidosis in children with type 1 diabetes mellitus in the Daegu-Gyeongbuk area during the coronavirus disease 2019 (COVID-19) pandemic: a retrospective cross-sectional study. J Yeungnam Med Sci. 2022;39(1):46-52. DOI:10.12701/yujm.2021.01221
9. Shestakova MV, Kononenko IV, Kalmykova ZA, et al. High level of glycated hemoglobin (HbA1c) in patients with COVID-19 is a marker of the severity of the infection but not an indicator of previous diabetes mellitus. Diabetes mellitus. 2020;23(6):504-13 (in Russian). DOI:10.14341/DM12702
10. Khaydarova FA, Alimova NU, Alieva AV, et al. Impact of COVID-19 infection on the development of type 1 diabetes mellitus in children and adolescents. Diabetes mellitus. 2022;25(1):21-6 (in Russian). DOI:10.14341/DM12785
11. Markova TN, Lysenko MA, Ivanova AA, et al. Prevalence of carbohydrate metabolism disorders in patients with new coronavirus infection. Diabetes mellitus. 2021;24(3):222-30 (in Russian). DOI:10.14341/DM12712
12. Da Porto A, Tascini C, Colussi G, et al. Relationship between cytokine release and stress hyperglycemia in patients hospitalized with COVID-19 infection. Front Med (Lausanne). 2022;9:988686. DOI:10.3389/fmed.2022.988686
13. Ilias I, Jahaj E, Kokkoris S, et al. Clinical Study of Hyperglycemia and SARS-CoV-2 Infection in Intensive Care Unit Patients. In Vivo. 2020;34(5):3029-32. DOI:10.21873/invivo.12136
14. Zhu L, She ZG, Cheng X, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020;31(6):1068-77.e3. DOI:10.1016/j.cmet.2020.04.021
15. Li H, Tian S, Chen T, et al. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19. Diabetes Obes Metab. 2020;22(10):1897-906. DOI:10.1111/dom.14099
16. Markova TN, Anchutina AA, Lysenko MA. Glyukoza plazmy natoshchak kak faktor riska neblagopriiatnogo iskhoda u gospitalizirovannykh patsiientov s COVID-19. Sbornik tezisov IX (XXVIII) Natsional'nyi diabetologicheskii kongress s mezhdunarodnym uchastiiem “Sakharnyi diabet i ozhireniie – neinfektsionnyie mezhdistsiplinarnyie pandemii XXI veka”. 05–08 sentiabria 2022 goda. Moscow, 2022 (in Russian).
17. Dedov II, Mokrysheva NG, Shestakova MV, et al. Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists. Diabetes mellitus. 2022;25(1):27-49 (in Russian).
18. Barrett CE, Koyama AK, Alvarez P, et al. Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years – United States, March 1, 2020 – June 28, 2021. MMWR Morb Mortal Wkly Rep. 2022;71(2):59-65. DOI:10.15585/mmwr.mm7102e2
19. Strongin LG, Nekrasova TA, Belikina DV, et al. Dysglycemia in COVID-19 and Type 2 Diabetes Mellitus: Peculiarities of the Glycemic Profile in Hospitalized Patients and the Role of Steroid-Induced Disorders. Problems of Endocrinology. 2022;68(2):56-65 (in Russian). DOI:10.14341/probl12840
20. Kuchay MS, Reddy PK, Gagneja S, et al. Short term follow-up of patients presenting with acute onset diabetes and diabetic ketoacidosis during an episode of COVID-19. Diabetes Metab Syndr. 2020;14(6):2039-41. DOI:10.1016/j.dsx.2020.10.015
2020;395(10229):1054-62. DOI:10.1016/S0140-6736(20)30566-3
2. Lee MH, Wong C, Ng CH, et al. Effects of hyperglycaemia on complications of COVID-19: A meta-analysis of observational studies. Diabetes Obes Metab. 2021;23(1):287-9. DOI:10.1111/dom.14184
3. Калмыкова З.А., Кононенко И.В., Скляник И.А., и др. Гипергликемия и возможные механизмы повреждения β-клеток у пациентов с COVID-19. Сахарный диабет. 2020;23(3):229-34 [Kalmykova ZA, Kononenko IV, Sklyanik IA, et al. Hyperglycemia and possible mechanisms of β-cell damage in patients with COVID-19. Diabetes mellitus. 2020;23(3):229-34 (in Russian)]. DOI:10.14341/DM12485
4. Govender N, Khaliq OP, Moodley J, Naicker T. Insulin resistance in COVID-19 and diabetes. Prim Care Diabetes. 2021;15(4):629-34. DOI:10.1016/j.pcd.2021.04.004
5. Senapati S, Banerjee P, Bhagavatula S, et al. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19. J Genet. 2021;100(1):12. DOI:10.1007/s12041-021-01262-w
6. Fadini GP, Morieri ML, Boscari F, et al. Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration. Diabetes Res Clin Pract. 2020;168:108374. DOI:10.1016/j.diabres.2020.108374
7. Sathish T, Kapoor N, Cao Y, et al. Proportion of newly diagnosed diabetes in COVID-19 patients: A systematic review and meta-analysis. Diabetes Obes Metab. 2021;23(3):870-4. DOI:10.1111/dom.14269
8. Lee MS, Lee R, Ko CW, Moon JE. Increase in blood glucose level and incidence of diabetic ketoacidosis in children with type 1 diabetes mellitus in the Daegu-Gyeongbuk area during the coronavirus disease 2019 (COVID-19) pandemic: a retrospective cross-sectional study. J Yeungnam Med Sci. 2022;39(1):46-52. DOI:10.12701/yujm.2021.01221
9. Шестакова М.В., Кононенко И.В., Калмыкова З.А., и др. Повышенный уровень гликированного гемоглобина (HbA1c) у больных с COVID-19 является маркером тяжести течения инфекции, но не индикатором предшествующего сахарного диабета. Сахарный диабет. 2020;23(6):504-13 [Shestakova MV, Kononenko IV, Kalmykova ZA, et al. High level of glycated hemoglobin (HbA1c) in patients with COVID-19 is a marker of the severity of the infection but not an indicator of previous diabetes mellitus. Diabetes mellitus. 2020;23(6):504-13 (in Russian)]. DOI:10.14341/DM12702
10. Хайдарова Ф.А., Алимова Н.У., Алиева А.В., и др. Влияние COVID-19-инфекции на развитие сахарного диабета 1 типа у детей и подростков. Сахарный диабет. 2022;25(1):21-6 [Khaydarova FA, Alimova NU, Alieva AV, et al. Impact of COVID-19 infection on the development of type 1 diabetes mellitus in children and adolescents. Diabetes mellitus. 2022;25(1):21-6 (in Russian)]. DOI:10.14341/DM12785
11. Маркова Т.Н., Лысенко М.А., Иванова А.А., и др. Распространенность нарушений углеводного обмена у пациентов с новой коронавирусной инфекцией. Сахарный диабет. 2021;24(3):222-30 [Markova TN, Lysenko MA, Ivanova AA, et al. Prevalence of carbohydrate metabolism disorders in patients with new coronavirus infection. Diabetes mellitus. 2021;24(3):222-30 (in Russian)]. DOI:10.14341/DM12712
12. Da Porto A, Tascini C, Colussi G, et al. Relationship between cytokine release and stress hyperglycemia in patients hospitalized with COVID-19 infection. Front Med (Lausanne). 2022;9:988686. DOI:10.3389/fmed.2022.988686
13. Ilias I, Jahaj E, Kokkoris S, et al. Clinical Study of Hyperglycemia and SARS-CoV-2 Infection in Intensive Care Unit Patients. In Vivo. 2020;34(5):3029-32. DOI:10.21873/invivo.12136
14. Zhu L, She ZG, Cheng X, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020;31(6):1068-77.e3. DOI:10.1016/j.cmet.2020.04.021
15. Li H, Tian S, Chen T, et al. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19. Diabetes Obes Metab. 2020;22(10):1897-906. DOI:10.1111/dom.14099
16. Маркова Т.Н., Анчутина А.А., Лысенко М.А. Глюкоза плазмы натощак как фактор риска неблагоприятного исхода у госпитализированных пациентов с COVID-19. Сборник тезисов IX (XXVIII) Национальный диабетологический конгресс с международным участием «Сахарный диабет и ожирение – неинфекционные междисциплинарные пандемии XXI века». 05–08 сентября 2022 года. М., 2022 [Markova TN, Anchutina AA, Lysenko MA. Glyukoza plazmy natoshchak kak faktor riska neblagopriiatnogo iskhoda u gospitalizirovannykh patsiientov s COVID-19. Sbornik tezisov IX (XXVIII) Natsional'nyi diabetologicheskii kongress s mezhdunarodnym uchastiiem “Sakharnyi diabet i ozhireniie – neinfektsionnyie mezhdistsiplinarnyie pandemii XXI veka”. 05–08 sentiabria 2022 goda. Moscow, 2022 (in Russian)].
17. Дедов И.И., Мокрышева Н.Г., Шестакова М.В., и др. Контроль гликемии и выбор антигипергликемической терапии у пациентов с сахарным диабетом 2 типа и COVID-19: консенсусное решение совета экспертов Российской ассоциации эндокринологов. Сахарный диабет. 2022;25(1):27-49 [Dedov II, Mokrysheva NG, Shestakova MV, et al. Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists. Diabetes mellitus. 2022;25(1):27-49 (in Russian)].
18. Barrett CE, Koyama AK, Alvarez P, et al. Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years – United States, March 1, 2020 – June 28, 2021. MMWR Morb Mortal Wkly Rep. 2022;71(2):59-65. DOI:10.15585/mmwr.mm7102e2
19. Стронгин Л.Г., Некрасова Т.А., Беликина Д.В., и др. Дисгликемия при COVID-19 и сахарном диабете 2 типа: особенности гликемического профиля у госпитализированных пациентов и роль стероид-индуцированных нарушений. Проблемы эндокринологии. 2022;68(2):56-65 [Strongin LG, Nekrasova TA, Belikina DV, et al. Dysglycemia in COVID-19 and Type 2 Diabetes Mellitus: Peculiarities of the Glycemic Profile in Hospitalized Patients and the Role of Steroid-Induced Disorders. Problems of Endocrinology. 2022;68(2):56-65 (in Russian)]. DOI:10.14341/probl12840
20. Kuchay MS, Reddy PK, Gagneja S, et al. Short term follow-up of patients presenting with acute onset diabetes and diabetic ketoacidosis during an episode of COVID-19. Diabetes Metab Syndr. 2020;14(6):2039-41. DOI:10.1016/j.dsx.2020.10.015
________________________________________________
2020;395(10229):1054-62. DOI:10.1016/S0140-6736(20)30566-3
2. Lee MH, Wong C, Ng CH, et al. Effects of hyperglycaemia on complications of COVID-19: A meta-analysis of observational studies. Diabetes Obes Metab. 2021;23(1):287-9. DOI:10.1111/dom.14184
3. Kalmykova ZA, Kononenko IV, Sklyanik IA, et al. Hyperglycemia and possible mechanisms of β-cell damage in patients with COVID-19. Diabetes mellitus. 2020;23(3):229-34 (in Russian). DOI:10.14341/DM12485
4. Govender N, Khaliq OP, Moodley J, Naicker T. Insulin resistance in COVID-19 and diabetes. Prim Care Diabetes. 2021;15(4):629-34. DOI:10.1016/j.pcd.2021.04.004
5. Senapati S, Banerjee P, Bhagavatula S, et al. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19. J Genet. 2021;100(1):12. DOI:10.1007/s12041-021-01262-w
6. Fadini GP, Morieri ML, Boscari F, et al. Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration. Diabetes Res Clin Pract. 2020;168:108374. DOI:10.1016/j.diabres.2020.108374
7. Sathish T, Kapoor N, Cao Y, et al. Proportion of newly diagnosed diabetes in COVID-19 patients: A systematic review and meta-analysis. Diabetes Obes Metab. 2021;23(3):870-4. DOI:10.1111/dom.14269
8. Lee MS, Lee R, Ko CW, Moon JE. Increase in blood glucose level and incidence of diabetic ketoacidosis in children with type 1 diabetes mellitus in the Daegu-Gyeongbuk area during the coronavirus disease 2019 (COVID-19) pandemic: a retrospective cross-sectional study. J Yeungnam Med Sci. 2022;39(1):46-52. DOI:10.12701/yujm.2021.01221
9. Shestakova MV, Kononenko IV, Kalmykova ZA, et al. High level of glycated hemoglobin (HbA1c) in patients with COVID-19 is a marker of the severity of the infection but not an indicator of previous diabetes mellitus. Diabetes mellitus. 2020;23(6):504-13 (in Russian). DOI:10.14341/DM12702
10. Khaydarova FA, Alimova NU, Alieva AV, et al. Impact of COVID-19 infection on the development of type 1 diabetes mellitus in children and adolescents. Diabetes mellitus. 2022;25(1):21-6 (in Russian). DOI:10.14341/DM12785
11. Markova TN, Lysenko MA, Ivanova AA, et al. Prevalence of carbohydrate metabolism disorders in patients with new coronavirus infection. Diabetes mellitus. 2021;24(3):222-30 (in Russian). DOI:10.14341/DM12712
12. Da Porto A, Tascini C, Colussi G, et al. Relationship between cytokine release and stress hyperglycemia in patients hospitalized with COVID-19 infection. Front Med (Lausanne). 2022;9:988686. DOI:10.3389/fmed.2022.988686
13. Ilias I, Jahaj E, Kokkoris S, et al. Clinical Study of Hyperglycemia and SARS-CoV-2 Infection in Intensive Care Unit Patients. In Vivo. 2020;34(5):3029-32. DOI:10.21873/invivo.12136
14. Zhu L, She ZG, Cheng X, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020;31(6):1068-77.e3. DOI:10.1016/j.cmet.2020.04.021
15. Li H, Tian S, Chen T, et al. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19. Diabetes Obes Metab. 2020;22(10):1897-906. DOI:10.1111/dom.14099
16. Markova TN, Anchutina AA, Lysenko MA. Glyukoza plazmy natoshchak kak faktor riska neblagopriiatnogo iskhoda u gospitalizirovannykh patsiientov s COVID-19. Sbornik tezisov IX (XXVIII) Natsional'nyi diabetologicheskii kongress s mezhdunarodnym uchastiiem “Sakharnyi diabet i ozhireniie – neinfektsionnyie mezhdistsiplinarnyie pandemii XXI veka”. 05–08 sentiabria 2022 goda. Moscow, 2022 (in Russian).
17. Dedov II, Mokrysheva NG, Shestakova MV, et al. Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists. Diabetes mellitus. 2022;25(1):27-49 (in Russian).
18. Barrett CE, Koyama AK, Alvarez P, et al. Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years – United States, March 1, 2020 – June 28, 2021. MMWR Morb Mortal Wkly Rep. 2022;71(2):59-65. DOI:10.15585/mmwr.mm7102e2
19. Strongin LG, Nekrasova TA, Belikina DV, et al. Dysglycemia in COVID-19 and Type 2 Diabetes Mellitus: Peculiarities of the Glycemic Profile in Hospitalized Patients and the Role of Steroid-Induced Disorders. Problems of Endocrinology. 2022;68(2):56-65 (in Russian). DOI:10.14341/probl12840
20. Kuchay MS, Reddy PK, Gagneja S, et al. Short term follow-up of patients presenting with acute onset diabetes and diabetic ketoacidosis during an episode of COVID-19. Diabetes Metab Syndr. 2020;14(6):2039-41. DOI:10.1016/j.dsx.2020.10.015
Авторы
Т.Н. Маркова*1,2, М.С. Стас1, В.В. Чибисова2, А.А. Анчутина1,2
1 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Е Евдокимова» Минздрава России, Москва, Россия;
2 ГБУЗ «Городская клиническая больница №52» Департамента здравоохранения г. Москвы, Москва, Россия
*markovatn18@yandex.ru
1 Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia;
2 Moscow City Clinical Hospital №52, Moscow, Russia
*markovatn18@yandex.ru
1 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Е Евдокимова» Минздрава России, Москва, Россия;
2 ГБУЗ «Городская клиническая больница №52» Департамента здравоохранения г. Москвы, Москва, Россия
*markovatn18@yandex.ru
________________________________________________
1 Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia;
2 Moscow City Clinical Hospital №52, Moscow, Russia
*markovatn18@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.